Focused on developing peripheral nerve regeneration and repair products, Axogen (Nasdaq:AXGN) announced that the Phase 3 RECON study met its primary endpoint in comparing its Avance nerve graft to conduits in digital nerve injuries. The primary endpoint was the return of sensory function based on static two-point discrimination. This test measures the ability to detect that two […]

Last week, we looked at how to make a career change from biotech to pharma. Specifically, we discussed how the line between biotech and pharma companies is getting more blurred, year by year. The two have more in common than many might think. That’s good news if you’re looking to make the move from biotech to […]

Lineage Cell Therapeutics’ CEO, Brian Culley, and I discussed the clinical-stage biotech’s existing plans for developing novel cell therapies for unmet medical needs. We discuss their cell therapy currently in clinical development for patients with acute spinal cord injuries as well as their cell therapy platform in development for cancer and why manufacturing large-scale amounts […]